| Not Yet Recruiting | Quality of Life Among Children With Inborn Error of Immunity NCT07262047 | Sohag University | — |
| Recruiting | An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous NCT07076446 | CSL Behring | Phase 4 |
| Recruiting | Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency NCT06092528 | Gazi University | N/A |
| Completed | Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France NCT06355323 | CHU de Reims | N/A |
| Recruiting | Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflamma NCT04902807 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Recruiting | Metabolic Profiling of Immune Responses in Immune-mediated Diseases NCT04864886 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Unknown | COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency NCT04724642 | Tel-Aviv Sourasky Medical Center | — |
| Completed | A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dos NCT04566692 | Grifols Therapeutics LLC | Phase 4 |
| Completed | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) NCT04561115 | Grifols Therapeutics LLC | Phase 3 |
| Unknown | Systematic Screening for Primary Immunodeficiencies in Patients Hospitalized for Severe Infections in Intensiv NCT04356053 | University Hospital, Montpellier | — |
| Completed | Minipooled-IVIG in Primary Immunodeficiency Disease NCT03896932 | Assiut University | N/A |
| Withdrawn | Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary I NCT03814798 | Grifols Therapeutics LLC | Phase 3 |
| Recruiting | Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies NCT03610802 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Severe Immune Cytopenia Registry Www.Sic-reg.Org NCT03576742 | Medical University of Graz | — |
| Completed | Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant NCT03330795 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Recruiting | NIAID Centralized Sequencing Protocol NCT03206099 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodef NCT03033745 | CSL Behring | Phase 4 |
| Completed | What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)? NCT03815357 | Murdoch Childrens Research Institute | — |
| Terminated | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study NCT03733249 | Bellicum Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO) NCT03054181 | GWT-TUD GmbH | — |
| Completed | IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia NCT02881437 | University Hospital, Lille | Phase 4 |
| Completed | Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency NCT02806986 | Grifols Therapeutics LLC | Phase 3 |
| Completed | CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN NCT03907241 | Octapharma | Phase 3 |
| Completed | Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% NCT02269163 | Prometic Biotherapeutics, Inc. | Phase 3 |
| Completed | Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency NCT02604810 | Grifols Therapeutics LLC | Phase 3 |
| Unknown | ASIS for GAMMAGARD in Primary Immunodeficiency NCT02123615 | ASIS Corporation | Phase 1 / Phase 2 |
| Completed | A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutane NCT02503293 | Octapharma | Phase 4 |
| Completed | The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 1 NCT03339778 | IMMUNOe Research Centers | — |
| Unknown | Diagnostic Immunization With Rabies Vaccine in Patients With PID NCT02490956 | Chulalongkorn University | Phase 4 |
| Terminated | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant NCT02065869 | Bellicum Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml NCT01985373 | Prothya Biosolutions | Phase 3 |
| Completed | Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) NCT01581593 | Kedrion S.p.A. | Phase 3 |
| Completed | Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immuno NCT01465958 | Grifols Therapeutics LLC | Phase 4 |
| Enrolling By Invitation | Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysre NCT00895271 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. NCT00278954 | Bio Products Laboratory | Phase 3 |